- InMed to test INM-750 in vitro, estimates clinical trials for 2018-2020
- ATERA SAS to develop 3D skin models to help pre-clinical tests of INM-750
- INM-750 being developed to treat skin disease epidermolysis bullosa, with a successful therapy having potential global market of $1 billion
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a biopharmaceutical company focused on identifying and commercializing prescription drugs using non-THC cannabinoids, recently reached a research and development agreement with tissue engineering company ATERA SAS of France (http://nnw.fm/5t7cL). The fundamental benefits of this agreement for InMed, as it eyes a clinical trial program, are a proprietary assessment tool, a biosynthesis manufacturing process, and drug development programs.
Vancouver-based InMed’s lead compound is INM-750, a proprietary topical cannabinoid product candidate aimed at treating skin disease epidermolysis bullosa (EB). EB is a skin disease which retards wound healing and can cause pain, itching, and inflammation. INM-750 may reverse the disease, for which there are currently no approved therapies. In its corporate presentation, InMed said that it sees a potential global market of $1 billion for INM-750, if approved.
Read the full article